fbpx

JUNE 22 Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Edge Therapeutics, Inc. (EDGE)

National securities law firm Glancy
Prongay & Murray LLP (“GPM”) reminds investors of the June
22, 2018 deadline to file a lead plaintiff motion in the class
action filed on behalf of investors that purchased Edge Therapeutics,
Inc. (“Edge Therapeutics” or the “Company”) (NASDAQ: EDGE)
securities between December 29, 2017 and March 27, 2018,
inclusive (the “Class Period”).

If you are a shareholder who suffered a loss, click here
to participate.

Investors suffering losses on their Edge Therapeutics investments are
encouraged to contact Lesley Portnoy of GPM to discuss their legal
rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

The complaint filed in this class action alleges that throughout the
Class Period, Defendants made false and/or misleading statements, as
well as failed to disclose material adverse facts about the Company’s
business, operations, and prospects. Specifically, Defendants failed to
disclose: (1) that the Company’s lead product candidate EG-1962 would
likely fail a futility analysis in connection with the NEWTON 2 study;
and, (2) that, as a result of the foregoing, the Company’s financial
statements and Defendants’ statements about Edge’s business, operations,
and prospects, were materially false and misleading at all relevant
times.

On March 28, 2018, Edge Therapeutics disclosed, “that a pre-specified
interim analysis on data from the Day 90 visit of the first 210 subjects
randomized and treated in the Phase 3 NEWTON 2 study of EG-1962
demonstrated a low probability of achieving a statistically-significant
difference compared to the standard of care in the study’s primary
endpoint, if the study is fully enrolled.” As a result, the Data
Monitoring Committee “recommended that the study be stopped based on its
conclusion that the study has a low probability of meeting its primary
endpoint.” Based on the DMC recommendation, Edge Therapeutics stated
that it has decided to discontinue the Phase 3 NEWTON 2 study.

On this news, shares of Edge Therapeutics fell $14.28 per share, or
nearly 92%, to close at $1.31 per share on March 28, 2018, thereby
injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Edge Therapeutics during the Class Period you
may move the Court no later than June 22, 2018 to ask the Court
to appoint you as lead. To be a member of the Class you need not take
any action at this time; you may retain counsel of your choice or take
no action and remain an absent member of the Class. If you wish to learn
more about this action, or if you have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East,
Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at
888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618006175/en/